Article
A guanidine-based coronavirus replication inhibitor which targets the nsp15 endoribonuclease and selects for interferon-susceptible mutant viruses.
PLoS pathogens - 1 Feb 2025
Van Loy Benjamin, Pujol Eugènia, Kamata Kenichi, Lee Xiao Yin, Bakirtzoglou Nikolai, Van Berwaer Ria, Vandeput Julie, Mestdagh Cato, Persoons Leentje, De Wijngaert Brent, Goovaerts Quinten, Noppen Sam, Jacquemyn Maarten, Ahmadzadeh Kourosh, Bernaerts Eline, Martín-López Juan, Escriche Celia, Vanmechelen Bert, Krasniqi Besir, Singh Abhimanyu K, Daelemans Dirk, Maes Piet, Matthys Patrick, Dehaen Wim, Rozenski Jef, Das Kalyan, Voet Arnout, Vázquez Santiago, Naesens Lieve, Stevaert Annelies
Abstract excerpt
The approval of COVID-19 vaccines and antiviral drugs has been crucial to end the global health crisis caused by SARS-CoV-2. However, to prepare for future outbreaks from drug-resistant variants and novel zoonotic coronaviruses (CoVs), additional therapeutics with a distinct antiviral mechanism are needed. Here, we report a novel guanidine-substituted diphenylurea compound that suppresses CoV replication by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
